课题基金 / 基金详情

Monoclonal Antibody

Monoclonal Antibody
单克隆抗体
批准号:
7928902
负责人:
Michel Gilliet
金额:
$8.82万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Michel Gilliet的其他基金

相似基金

相关文献

中文摘要
翻译
单抗已经成为生物化学、分子生物学和医学中必不可少的工具,并且 基础和临床研究人员已将其广泛用于研究、诊断和临床治疗。 单抗中心(MABF)于2003年正式成立。它的主要目标是生产 以高通量和高效的方式高亲和抗体,同时专注于产品质量 和服务。MABF最大限度地减少了繁琐的实际操作程序,并对协议进行了标准化,以提供 结果准确,重现性好。具体目标和长期目标是:1)产生高亲和力 为广泛的研究项目定制单抗;2)使研究人员能够访问 在杂交瘤生产和方法方面经验丰富的人员,并排除任何抗原或 筛查相关问题;3)以有竞争力的价格提供优质服务;4)通过以下方式获得洞察力 产生的抗体,转化为不同分子在正常和病理系统中所起的作用,以及 为最终的治疗或诊断确定他们的特征。MABF占地726平方英尺。英国《金融时报》在SCRB 1中, 位于南校区的癌症免疫研究中心(CCIR)配备了定制的 实验室服务、中央组织培养室、液氮储罐室和玻璃器皿清洗 和消毒设施,所有这些都可供MABF使用。MABF的工作人员由Michel Gilliet组成, MD,核心领导,负责核心的方向,并担任监督委员会主席。Gilliet博士 定期与Bover博士和Long Vien会面,讨论MABF的整体运作情况。劳拉·博弗 博士,核心联合领导,负责MABF的整体运作,负责进度报告,感兴趣 研究人员在设施的使用中,并确保程序和政策的变化是由 监督委员会。她和Long Vien一起负责短期和长期的规划和 该设施的增长。核心经理Long Vien负责核心的日常运营。 他与博弗博士一起,为不同的用户需求规划和设计技术程序。 詹姆斯·怀甘特,研究实验室协调员,负责技术程序并制定 与用户的第一次接触。他记录设施的所有活动,并跟踪用户,收集 与出版物有关的信息,以及用于支付服务的赠款。罗莎·穆尼奥斯,研究 助理,负责技术程序(动手)。未来的计划是重新设计我们的网站以 提供更多关于服务和好处的信息,以努力接触到MDACC内部的更多研究人员。 该设施还需要就其服务的独特增值功能进行更广泛的沟通。
英文摘要
Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility. Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects; 2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues; 3) to provide quality services at competitive prices; 4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Monoclonal Antibody
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
海外基金